Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating KarXT for acutely psychotic schizophrenia in Japanese adults; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Schizophrenia | Phase 3 | Status: RECRUITING